© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 18, 1411-1418,
September 19, 2001
© 2001 Oxford University Press
REPORT |
Tobacco Carcinogen-Detoxifying Enzyme UGT1A7 and Its Association With Orolaryngeal Cancer Risk
Affiliations of authors: Z. Zheng, J. Y. Park, P. Lazarus, Divisions of Cancer Control and Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Interdisciplinary Oncology Program and Departments of Biochemistry and Pharmacology and Therapeutics, University of South Florida, Tampa; C. Guillemette, Oncology and Molecular Endocrinology Research Center, CHUL Research Center (CHUQ), School of Pharmacy, Laval University, PQ, Canada; S. P. Schantz, Department of Otolaryngology, The New York Eye and Ear Infirmary, New York City.
Correspondence to: Philip Lazarus, Ph.D., Divisions of Cancer Control and Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, MRC-2E, 12902 Magnolia Dr., Tampa, FL 33612 (e-mail: plazarus{at}moffitt.usf.edu).
Background: UDP-glucuronosyltransferase 1A7 (UGT1A7) detoxifies several tobacco carcinogens. We determined whether UGT1A7 expression is observed in normal orolaryngeal tissue and whether UGT1A7 allelic variations are associated with the risk for orolaryngeal cancer. Methods: UGT1A7 expression in normal orolaryngeal tissue was determined by semiquantitative reverse transcription–polymerase chain reaction (PCR). Buccal cell DNA isolated from 194 case subjects with orolaryngeal cancer and from 388 control subjects who were matched by sex, age, and race was subjected to UGT1A7 genotyping with the use of combined PCR–restriction fragment length polymorphism and allelic discrimination analysis. All statistical tests were two-sided. Results: UGT1A7 messenger RNA was expressed at similar levels in the esophagus, tongue, tonsil, floor of the mouth, and larynx. Genotyping revealed the presence of three variant reduced-activity UGT1A7 alleles in both Caucasians and African-Americans. Individuals with any of the predicted low-activity UGT1A7 genotypes had an increased risk of orolaryngeal cancer (odds ratio [OR] = 3.7; 95% confidence interval [CI] = 1.7 to 8.7) relative to subjects with the wild-type genotype. Both Caucasians and African-Americans with the low-activity genotypes had statistically significantly increased orolaryngeal cancer risk compared with Caucasians and African-Americans with the wild-type genotype (OR = 2.8 [95% CI = 1.1 to 7.6] and OR = 6.2 [95% CI = 1.2 to 31], respectively). For subjects with the predicted low-activity genotypes, the risks of oral cavity cancer (OR = 4.2; 95% CI = 1.7 to 10) and laryngeal cancer (OR = 3.7; 95% CI = 0.99 to 14) were similar. There was no association between UGT1A7 genotype and orolaryngeal cancer risk in never smokers, whereas subjects with predicted low-activity UGT1A7 genotypes who were light smokers (OR = 3.7; 95% CI = 1.1 to 12) or heavy smokers (OR = 6.1; 95% CI = 1.5 to 25) had an increased risk. Conclusions: The tissue expression of UGT1A7 is consistent with the possibility of a physiologic role in orolaryngeal cancer. Variations in the UGT1A7 gene that reduce UGT1A7 activity may affect the risk of smoking-related orolaryngeal cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. C. Olson, R. W. Dellinger, Q. Zhong, D. Sun, S. Amin, T. E. Spratt, and P. Lazarus Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene Drug Metab. Dispos., October 1, 2009; 37(10): 1999 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. LACKO, M. B. O. OPHUIS, W. H.M. PETERS, and J. J. MANNI Genetic Polymorphisms of Smoking-related Carcinogen Detoxifying Enzymes and Head and Neck Cancer Susceptibility Anticancer Res, February 1, 2009; 29(2): 753 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gemignani, S. Landi, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, L. Foretova, V. Janout, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes Carcinogenesis, June 1, 2007; 28(6): 1287 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Girard, L. Villeneuve, M. H. Court, L.-C. Fortier, P. Caron, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and C. Guillemette THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER Drug Metab. Dispos., July 1, 2006; 34(7): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Dellinger, J.-L. Fang, G. Chen, R. Weinberg, and P. Lazarus IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) IN THE DETOXIFICATION OF POLYCYCLIC AROMATIC HYDROCARBONS: DECREASED GLUCURONIDATIVE ACTIVITY OF THE UGT1A10139LYS ISOFORM Drug Metab. Dispos., June 1, 2006; 34(6): 943 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Han, H.-S. Lim, E. S. Shin, Y.-K. Yoo, Y. H. Park, J.-E. Lee, I.-J. Jang, D. Ho Lee, and J. Soo Lee Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin J. Clin. Oncol., May 20, 2006; 24(15): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen, D. Beaton, N. Nguyen, K. Senekeo-Effenberger, E. Brace-Sinnokrak, U. Argikar, R. P. Remmel, J. Trottier, O. Barbier, J. K. Ritter, et al. Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus J. Biol. Chem., November 11, 2005; 280(45): 37547 - 37557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Verlaan, J P H Drenth, K Truninger, M Koudova, H-U Schulz, M Bargetzi, B Kunzli, H Friess, M Cerny, A Kage, et al. Polymorphisms of UDP-glucuronosyltransferase 1A7 are not involved in pancreatic diseases J. Med. Genet., October 1, 2005; 42(10): e62 - e62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, and A. J. Duffield-Lillico Levels of Prostaglandin E Metabolite, the Major Urinary Metabolite of Prostaglandin E2, Are Increased in Smokers Clin. Cancer Res., August 15, 2005; 11(16): 6087 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Butler, Y. Duguay, R. C. Millikan, R. Sinha, J.-F. Gagne, R. S. Sandler, and C. Guillemette Joint Effects between UDP-Glucuronosyltransferase 1A7 Genotype and Dietary Carcinogen Exposure on Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. O. Lankisch, A. Vogel, S. Eilermann, A. Fiebeler, B. Krone, A. Barut, M. P. Manns, and C. P. Strassburg Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene Mol. Pharmacol., May 1, 2005; 67(5): 1732 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Almahmeed, J. O. Boyle, E. G. Cohen, J. F. Carew, B. Du, N. K. Altorki, L. Kopelovich, J.-L. Fang, P. Lazarus, K. Subbaramaiah, et al. Benzo[a]pyrene phenols are more potent inducers of CYP1A1, CYP1B1 and COX-2 than benzo[a]pyrene glucuronides in cell lines derived from the human aerodigestive tract Carcinogenesis, May 1, 2004; 25(5): 793 - 799. [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, N. Kato, Y. Hoshida, M. Otsuka, H. Taniguchi, M. Moriyama, S. Shiina, T. Kawabe, Y. M. Ito, and M. Omata UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma in Japanese Patients with Hepatitis C Virus Infection Clin. Cancer Res., April 1, 2004; 10(7): 2441 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Wells, P. I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. Roy Chowdhury, et al. GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE Drug Metab. Dispos., March 1, 2004; 32(3): 281 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Wallig Glucuronidation and Susceptibility to Chemical Carcinogenesis Toxicol. Sci., March 1, 2004; 78(1): 1 - 2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wiener, J.-L. Fang, N. Dossett, and P. Lazarus Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes Cancer Res., February 1, 2004; 64(3): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Villeneuve, H. Girard, L.-C. Fortier, J.-F. Gagne, and C. Guillemette Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 117 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jinno, M. Saeki, Y. Saito, T. Tanaka-Kagawa, N. Hanioka, K. Sai, N. Kaniwa, M. Ando, K. Shirao, H. Minami, et al. Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 688 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Tukey, C. P. Strassburg, and P. I. Mackenzie Pharmacogenomics of Human UDP-Glucuronosyltransferases and Irinotecan Toxicity Mol. Pharmacol., September 1, 2002; 62(3): 446 - 450. [Full Text] [PDF]
|
|